FogPharma is a biopharmaceutical company dedicated to advancing the potential of Helicon therapeutics, a groundbreaking class of peptides that facilitate effective cell entry and the modulation of critical protein interactions within cells. The company aims to transform treatment possibilities for patients by targeting previously undruggable intracellular proteins, specifically in the context of complex diseases like cancer. FogPharma's lead candidate, FOG001, a TCF-blocking catenin inhibitor, is currently in clinical trials for advanced solid tumors, including colorectal cancer. Operating from Cambridge, Massachusetts, FogPharma employs advanced machine learning and computational techniques to accelerate its research and development processes. The company fosters a collaborative and innovative environment, emphasizing the importance of patient outcomes and a commitment to pioneering new therapeutic approaches in precision medicine.